MileCell Bio will exhibit at the AACR Annual Meeting 2026, taking place April 17–22, 2026, at the San Diego Convention Center in San Diego, California. As the premier global gathering in oncology, AACR brings together researchers and industry leaders across cancer biology, translational science, and clinical development to advance breakthroughs that improve patient outcomes.
Aligned with this year’s theme — “Precision • Partnership • Purpose: Advancing Cancer Science to Save Lives Globally” — AACR 2026 highlights key areas including precision oncology, immunotherapy, early detection, and translational drug development.
As oncology research increasingly shifts toward tumor microenvironment modulation, immune-based therapies, and mechanism-driven drug development, there is a growing need for high-quality, physiologically relevant in vitro systems that can support reproducible and translatable data generation.
Enabling Oncology Discovery and Translational Research
At AACR 2026, MileCell Bio will highlight a portfolio of biological research materials designed to support key oncology workflows:
- Primary hepatocytes with high metabolic activity
→ supporting oncology drug metabolism, DDI risk, and translational PK studies - Liver subcellular fractions (S9, microsomes)
→ enabling metabolite identification and ADME characterization of oncology pipelines - Animal-derived immune cells (PBMCs, splenocytes)
→ supporting immuno-oncology research, tumor microenvironment studies, and cell therapy development - Magnetic bead–based immune cell isolation tools
→ enabling high-purity T cell and immune subset isolation for functional assays - CGT-grade, serum-free cryopreservation media
→ supporting standardized workflows in cell therapy and immune-based assays
We invite oncology researchers, translational scientists, and drug development teams to visit Booth #3957 to discuss how MileCell Bio solutions can support:
- Immuno-oncology assay development
- ADME and metabolism studies for oncology drugs
- Cell therapy and immune cell workflows We look forward to engaging with the global cancer research community at AACR 2026.
